SCHEMBL15020805

SCHEMBL15020805

CCOCc1nn2c(-c3cccc(OC)c3)cc(N3CCCC3CO)nc2c1-c1ccc(OC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 2/20 0.38
▸ SPHK2 Q9NRA0 1/20 0.38
▸ MAPT P10636 4/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ PLAT P00750 1/20 0.36
▸ TRPV1 Q8NER1 2/20 0.36
▸ FPR2 P25090 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ SRC P12931 2/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ PIK3C2B O00750 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020880 0.95 CDK1 (0.37) CDK1SPHK2MAPTMAPK1TRPV1
SCHEMBL15020885 0.94 HCRTR1 (0.37) CDK1SPHK2MAPTMAPK1PLAT
SCHEMBL15020883 0.94 HCRTR1 (0.37) CDK1SPHK2MAPTMAPK1PLAT
SCHEMBL15020757 0.93 FPR2 (0.39) CDK1SPHK2MAPTMAPK1PLAT
SCHEMBL15020575 0.93 PLAT (0.42) CDK1SPHK2MAPTMAPK1PLAT
SCHEMBL15020534 0.91 SPHK2 (0.41) CDK1SPHK2MAPTMAPK1PLAT
SCHEMBL15021381 0.90 FPR2 (0.44) CDK1MAPTMAPK1PLATTRPV1
SCHEMBL15020577 0.88 KDM4E (0.38) MAPTFPR2SCN9AADORA3ADORA2A
SCHEMBL27908976 0.87 PLAT (0.41) CDK1SPHK2MAPTMAPK1PLAT
SCHEMBL15020996 0.86 PLAT (0.41) CDK1SPHK2MAPTMAPK1PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 CDK1 1085/4885SPHK2 148/4885MAPT 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback